Sellas ovarian cancer and mesothelioma GPS combined trial yields positive results

Compilation | Fan Dongdong

A few days ago, Sellas Life Sciences Group announced the positive results of phase I/II trials of galinpepimut-S (GPS) combined with Keytruda

These two trials enrolled 11 people and 4 people, and although they are small in scale, their studies are more extensive

GPS is a Wilms Tumor-1 (WT1) targeted peptide immunotherapeutic agent

An interim analysis at the 15-week follow-up showed that nearly 64% of patients were stable or responded to the combination therapy

Sellas focuses on the development of the Wilms Tumor1 antigen, which was previously designated by the National Cancer Institute as the first immunotherapy target

GPS is composed of four peptide chains, two of which (CD4+ and CD8+) are responsible for inducing a strong innate response to WT1 antigen and obtaining a variety of HLA types

GPS works in conjunction with immunotherapy (especially Opdivo and Keytruda) to regulate the hostile tumor microenvironment

Stergiou said, “The current phase III trial is mainly for patients with acute myeloid leukemia in the second remission phase.

Reference source: Sellas Reports Promising Data from Combination Trials in Ovarian Cancer and Mesothelioma